EMD Serono
One Technology Place
Rockland
MA
02370
United States
Tel: 800-283-8088
Website: https://www.emdserono.com/us-en
241 articles about EMD Serono
-
CORPAK MedSystems Acquires Merck Serono's UK Gastroenterology Sales and Distribution Operation
10/2/2012
-
Parkinson's Specialist Spins Out From Merck Serono's Soon-to-close R&D Operations
7/30/2012
-
Position of Merck Serono Concerning the Recommendation Made by CRCT of Geneva
7/27/2012
-
Quintiles, Inc. Offers 100 Jobs to Merck Serono Employees Affected by Cuts
6/27/2012
-
Merck Serono Confirms Geneva Closure, Creates Start-up Fund
6/19/2012
-
Merck Serono Staff Mull Further Strike Action
6/11/2012
-
Merck Serono Staff Has Solutions to Stop Layoffs
6/7/2012
-
Dr. Reddy's Laboratories Ltd., Merck Serono in Pact to Develop Biotech Drug Copies
6/6/2012
-
Dr. Annalisa Jenkins, Executive Vice President, Head of Global Drug Development and Medical for Merck Serono, Honored by Gilda’s Club New York City
5/23/2012
-
Pharmaceutical Company Merck Serono Signs an Agreement to Use Kadimastem's Platform for Drug Screening
4/30/2012
-
Merck KGaA to Close Merck Serono's Swiss HQs and Axe 580 Jobs
4/25/2012
-
Asterand plc’s Subsidiary BioSeek, LLC. Extends Collaboration with Merck Serono
3/28/2012
-
Merck Serono Fertility Treatment Pergoveris® Receives Marketing Approval in Russia
3/16/2012
-
Mendor Announces Partnership with Merck Serono in the UK
2/14/2012
-
Frost & Sullivan Honours Merck Serono for Its Achievements in the Treatment of Infertility
1/30/2012
-
Ablynx and Merck Serono Select a Novel Nanobody Candidate, ALX-0761, for Pre-Clinical Development
12/13/2011
-
Ablynx Signs Discovery Pact Worth $69 Million With Merck Serono
11/9/2011
-
Merck Serono and Ono Pharmaceutical Company, Ltd. Sign Separate Agreements Worth $25 Million for MS and Cancer Drugs
10/5/2011
-
Merck Serono: New Data Inspire Global Experts to Call for Improved Education, Awareness and Support for Head and Neck Cancer Patients
9/26/2011
-
Merck Serono Buys Potential Copaxone Competitor from Bankrupt Peptimmune, Inc.
9/19/2011